Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘Immunotherapy Portfolio Strategy’

Learnings from IO combinations and where we’re headed

The twin effects of rapid development and increasing complexity in cancer research can be seen as both a good and a bad thing because while both negative and positive results might be a helpful window into where current research might be (or should be currently headed), it also means that for industry project teams, clinical development plans are much more challenging to put together.

Rising or setting of key targets and molecules?

This is also a reflection of the current state of research in immuno-oncology – things are much more complicated than many people realised even just a decade ago – as we slowly peel off the layers of the onion to reveal yet more layers and unknowns.

In short, we still don’t know what we don’t know on many key issues, never mind how various cells might interact and communicate in both health and disease.

With this in mind, I wanted to take a moment and offer a top-line review of six key areas to watch out for as we head towards the Fall conference season…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

One of the interesting questions raised by the recently announced and much-discussed Juno/Celgene collaboration is whether you really need a Chimeric Antigen Receptor (CAR) T cell therapy in your portfolio to succeed as a global cancer immunotherapy company?

One leading cancer immunotherapy company that believes you don’t is Roche.  At ASCO 2015 I had the privilege to talk about this with a leading cancer scientist, William Pao, MD PhD (pictured below). Dr Pao formerly worked with Nobel Prize-winning scientist Harold Varmus at Memorial Sloan Kettering, and subsequently led the Hematology-Oncology Division at Vanderbilt. He joined Roche in July 2014 to lead their early development of innovative oncology new products (see press release).

 

I particularly enjoyed Dr Pao’s discussion of the T-cell centric strategic framework around which the Roche/Genentech cancer immunotherapy portfolio strategy is based.

This is the first in a series of interviews with scientific leaders at companies at the forefront of cancer research.

To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

error: Content is protected !!